USPTO serial 75142241
10 PHILD
Reviewed by CopyMark Law Group
Reg. 2347940Status 710
- Filing date
- Status date
- Registration date
- May 9, 2000
- Examiner
- SALEMI, DOMINICK
- Law office
- SCANNING ON DEMAND
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with 10 PHILD?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Kyoto City, Kyoto Pref., JP
Kyoto City, Kyoto Pref., JP
Kyoto city, Kyoto Pref., JP
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John T. Miller
STACEY R HALPERN KNOBBE, MARTENS, OLSON & BEAR LLP2040 MAIN ST 14TH FLIRVINE, CA 92614UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | drugs for medical purposes, namely, drugs for central nervous system, namely, general anesthetics, hypnotics and sedatives, anti-epileptics, antipyretics and analgesics, nervous system stimulants, analeptics and anti-dizziness agents; drugs for peripheral nervous system, namely, local anesthetics, skeletal muscle relaxants, autonomics, antispasmodics, diaphoretics and anhidrotics; drugs for sensory organs, namely, agents for ophthalmic use and agents for otic and nasal use; drugs used in allergy, namely, anti-histamines and agents for stimulation therapy; drugs affecting circulatory organs, namely, cardiotonics, agents for arrhythmia, diuretics, hypotensors, vasosupporters, vasoconstrictors and cerebral hemorrhage prophylactic; agents affecting respiratory organs, namely, respiratory stimulants, antitussives and expectorants and cough wheat gluten; agents for digestive organs, namely, agents for dental use, agents for oral use, stomachics and digestives, antacids, anti-emetics, emetics, choleretics, antidiarrheals, purgatives, clysters, stomach and bowels wash powder, tooth prophylactic, stomatic refrigerant, and stomatic cleanser; hormone preparations, namely, pituitary hormone preparations, salivary gland hormone preparations, thyroid and accessory thyroid hormone preparations, pancreas hormone preparations, adrenal hormone preparations, androgens, estrogens and mixed hormone preparations; agents for urinary, genital and anal organs, namely, urinary antiseptics, oxytocics, agents affecting menstruation, contraceptives and anti-hemorrhoidics; agents affecting epidermis, namely, disinfectants, dermatics for purulence, analgesics, anti-itchings, astringents, cataplasms, anti-dermoinfectives, corrosives, hair remedies, bath preparations, medicated baby powder, medicated baby oil, medicated soap of the Japanese pharmacopoeia; vitamin preparations, namely, vitamin A preparations, vitamin B preparations, vitamin C preparations, vitamin D preparations, composite vitamin preparations compounded of water soluble and fat soluble vitamins, mixed vitamin preparations compounded of water soluble and fat soluble vitamins and cod-liver oil drops; amino acids and preparations, namely, lysine, methionin, tryptophane and threonine; preparations, nutrients, tonics and alternatives, namely, calcium, mineral, saccharide, organic acid, proteins, amino acids, organotherapeutics, chondroitin, foodstuff solidifying agent, medicated wine and royal jelly; agents relating to blood, namely, blood substitutes, hemostatics, anticoagulants and blood-plasma; agents affecting metabolism, namely, lipotropic factor preparations, antidotes, agents for treatment of habitual intoxication, lactogoques and enzyme preparations; agents for activating cellular function, namely, chlorophyll preparations and dyes; anti-cancer and anti-sarcoma tumor suppressing agents; agents used in lesion due to physical stimuli, namely, agents used in thermoplegia and agents used in radiation sickness; agents used in lesion due to chemical stimuli, namely, anti-benzolismus, anti-arsenium and anti-chlorine poisoning; antibiotics and preparations, namely, penicillin, streptomycin, chloramphenicol, erythromycin, thiolutin, tetracycline, colistin-polymyxin, mixed antibiotic, salkomycin and trichomycin; chemotherapeutics agents and preparations, namely, sulfonamide, antituberculotic, antisyphilitics and antiliprotic; biological products, namely, vaccines, toxins, toxoids, antitoxins, antibacterial sera, diagnostic acids for biological tests and mixed biological preparations; agents against parasites, namely, antiprozoals and anthelmintics; agents for dispensing use, namely, excipients, ointment bases, solvents, flavoring agents, deodorizer and coloring agents; diagnostic aids, namely, X-ray contrast media, diagnostic reagents and diagnostic media; labeled isotope substance for treatment and diagnosis; narcotics, namely, opium alkaloids, derivatives and preparations, coca alkaloids, derivatives and preparations and synthetic narcotics; crude drug, charred drug and moxa; veterinary drugs; agents for agriculture or public health, namely, disinfectants, insecticides, fumigants, rodenticides, herbicides, germination controllers, hormones for plants, plants rearing agents, soil improving agents, moth repellents, deodorants and antiseptics; dental restoration compounds, namely, dental cements, dental prosthetic and filling materials; oblates, namely, thin wafers made from wheatmeal or capsules for the purpose of wrapping the aforementioned drugs for medical purposes; gauze; capsules for containing aforementioned drugs for medical purposes; ear bandages; menstruation tampons; sanitary napkins; panties incorporating sanitary pads; absorbent cotton for medical purposes; adhesive medical plasters; bandages for dressings; liquid wound dressings; adult diapers; semen for artificial insemination; powdered milk for babies; menstruation bandages | SECTION 8 - CANCELLED | — |
| 010 | dental wax and artificial tooth materials; medical oil paper used for medical purposes; sanitary masks used by people with colds or other contagious illnesses; eye patches; bracelets, namely, orthopedic supporters for medical purposes | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Feb 17, 2007 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Apr 14, 2006 | CFIT | CASE FILE IN TICRS | — |
| Nov 16, 2004 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Apr 6, 2004 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 9, 2000 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 15, 2000 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 14, 2000 | NPUB | NOTICE OF PUBLICATION | — |
| Oct 23, 1999 | 1.BD | Sec. 1(B) CLAIM DELETED | — |
| Dec 1, 1998 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 5, 1998 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 20, 1998 | CNSL | LETTER OF SUSPENSION MAILED | — |
| Mar 13, 1998 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 10, 1997 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Aug 11, 1997 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 11, 1997 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 16, 1997 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 10, 1997 | DOCK | ASSIGNED TO EXAMINER | — |